Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fundamentals of engineered T cell therapies: From basic design to bells and whistles.

Advances in pharmacology (San Diego, Calif.)·2026
Same author

Bispecific antibody engineered extracellular vesicles redirect T cells to prevent postoperative epidural fibrosis.

Nature communications·2026
Same author

Kidney Transplantation in Two Highly Sensitized Candidates after CAR T-Cell Therapy.

The New England journal of medicine·2026
Same author

Spatial atlas of diabetic kidney disease reveals a B cell-rich subgroup.

Nature·2026
Same author

Novel RHCE*cE(341A) allele.

Transfusion·2026
Same author

Engineered extracellular vesicles displaying bi-specific T-cell engagers for targeted therapy of B-cell malignancies.

Experimental hematology & oncology·2026

Related Experiment Video

Updated: Apr 12, 2026

Enrichment of Native Lipoprotein Particles with microRNA and Subsequent Determination of Their Absolute/Relative microRNA Content and Their Cellular Transfer Rate
11:13

Enrichment of Native Lipoprotein Particles with microRNA and Subsequent Determination of Their Absolute/Relative microRNA Content and Their Cellular Transfer Rate

Published on: May 9, 2019

9.4K

Lipoprotein apheresis.

Vijay G Bhoj1, Bruce S Sachais

  • 1Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Current Atherosclerosis Reports
|May 26, 2015
PubMed
Summary
This summary is machine-generated.

Lipoprotein apheresis selectively removes harmful lipoproteins like LDL and Lp(a) from blood. This extracorporeal therapy helps manage familial hypercholesterolemia and other high cholesterol conditions, limiting atherosclerotic complications.

More Related Videos

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.8K
Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification
10:39

Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification

Published on: November 28, 2016

11.9K

Related Experiment Videos

Last Updated: Apr 12, 2026

Enrichment of Native Lipoprotein Particles with microRNA and Subsequent Determination of Their Absolute/Relative microRNA Content and Their Cellular Transfer Rate
11:13

Enrichment of Native Lipoprotein Particles with microRNA and Subsequent Determination of Their Absolute/Relative microRNA Content and Their Cellular Transfer Rate

Published on: May 9, 2019

9.4K
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.8K
Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification
10:39

Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification

Published on: November 28, 2016

11.9K

Area of Science:

  • Cardiovascular Medicine
  • Nephrology
  • Internal Medicine

Background:

  • Lipoprotein apheresis is an extracorporeal therapy that selectively removes apolipoprotein B (apo B)-containing lipoproteins from patient plasma.
  • It differs from plasma exchange by targeting specific lipoproteins, not all plasma proteins.
  • This therapy is crucial for managing severe hyperlipidemias and preventing atherosclerotic complications.

Purpose of the Study:

  • To provide a comprehensive overview of lipoprotein apheresis.
  • To detail its indications, techniques, efficacy, and adverse events.
  • To discuss guidelines and patient selection criteria for this therapy.

Main Methods:

  • Review of existing literature and clinical guidelines on lipoprotein apheresis.
  • Analysis of therapeutic outcomes and safety profiles.
  • Comparison with standard plasma exchange.

Main Results:

  • Lipoprotein apheresis effectively reduces LDL, vLDL, and Lp(a) levels.
  • It is indicated for familial hypercholesterolemia and other hyperlipidemic conditions.
  • Efficacy in limiting/reversing atherosclerotic complications is demonstrated.

Conclusions:

  • Lipoprotein apheresis is a vital treatment option for specific hyperlipidemic patients.
  • Careful patient selection based on guidelines is essential for optimal outcomes.
  • Understanding indications, techniques, and adverse events is key for effective application.